Dosimetry of an Extracapsular Anulus Following Permanent Prostate Brachytherapy
| Autor: | Edward Adamovich, Robert Grammer, Richard L. Anderson, Zachariah A. Allen, K.E. Wallner, Wayne M. Butler, Robert W. Galbreath, Lawrence D. True, B.S. Kurko, Gregory S. Merrick |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Radioisotopes Cancer Research business.industry medicine.medical_treatment Brachytherapy Planning target volume Prostatic Neoplasms Permanent prostate brachytherapy Radiation Dosage medicine.disease Iodine Radioisotopes Prostate cancer medicine.anatomical_structure Oncology Periprostatic Prostate medicine Humans Dosimetry business Nuclear medicine Postimplant dosimetry Palladium |
| Zdroj: | American Journal of Clinical Oncology. 30:228-233 |
| ISSN: | 0277-3732 |
| Popis: | PURPOSE Recent studies have suggested that extracapsular brachytherapy treatment margins correlate with biochemical control. It is likely that volumetric geographic dosimetric parameters will be more robust than selected radial measurements. Accordingly, we evaluated extracapsular volumetric dosimetric parameters in low-risk patients. MATERIALS AND METHODS A total of 263 low-risk prostate cancer patients randomized to Pd-103 versus I-125 were implanted with a brachytherapy target volume consisting of the prostate with a 5-mm periprostatic margin. The median follow-up was 4.2 years. All patients were implanted at least 3 years prior to analysis. Within 2 hours of implantation, an axial CT was obtained for postimplant dosimetry. A 5-mm three-dimensional periprostatic anulus was constructed around the prostate and evaluated in its entirety and in 90 degrees segments. Prostate and anular dosimetric parameters consisted of V100/V150/V200 and D90. Biochemical progression-free survival (bPFS) was defined as a PSA < or =0.50 ng/mL after nadir. RESULTS The Pd-103 and I-125 arms were well-matched in terms of clinical, biochemical, and pathologic presentation. Six-year bPFS was 96.8% versus 99.2% for I-125 versus Pd-103 (P = 0.149). The most recent median posttreatment PSA was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|